You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Humanized Monoclonal Antibody to Treat Acinetobacter Infections

    SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC            Topic: NIAID

    DESCRIPTIONprovided by applicantNational surveillance data confirm thatof Abaumannii isolates from US intensive care units are extreme drug resistanceXDRfar higher than other pathogensAt leastandcases of XDR Abaumannii infections occur annually in the US and globallyin developed countriesrespectivelyThese infections result inanddeaths and excess healthcare costs of $million and $million in the US ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Personalized dosing of dichloroacetate for the treatment of rare and common diseases

    SBC: Medosome Biotec, LLC            Topic: NICHD

    Project Abstract/Summary Pyruvate dehydrogenase complex (PDC) deficiency (PDCD) is a rare disease of mitochondrial energy failure in which the life expectancy of affected children is severely truncated from unrelenting lactic acidosis and/or from progressive neurological and neuromuscular degeneration. Treatment of PDCD remains a serious, unmet, challenge. Dichloroacetate (DCA) represents the firs ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens

    SBC: SILVER LAKE RESEARCH CORPORATION            Topic: NIAID

    PROJECT SUMMARY ABSTRACT This proposal describes Phase II of the development of a rapid immunoassay test kit for the determination oflactam antibiotic resistanceto be used as a point of care diagnostic test for urinary tract infectionsTodayantibiotics for UTI are prescribed empiricallywith no diagnostics available to clinicians to avoid treating resistant infections with the very drug to which the ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms

    SBC: NeuroSigma, Inc.            Topic: 101

    DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Multi-Modality Image Data Fusion and Machine Learning Approaches for Personalized Diagnostics and Prognostics of MCI due to AD

    SBC: MS Technologies Corporation            Topic: R

    Alzheimer’s Disease (AD) is a devastating neurodegenerative disease. The greatest treatment potential lies in early stages before irreversible brain damage occurs. Early treatment requires early detection of the disease. Imaging holds great promise for capturing early signs of AD. This capability can be substantially strengthened by integrating neuroimages of different modalities that characteri ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Development and testing of a behavioral activation mobile therapy for elevated depressivesymptoms

    SBC: MOUNTAINPASS TECHNOLOGY LLC            Topic: 104

    PROJECT SUMMARY/ABSTRACT Depression is the leading cause of disability worldwide, with more than 300 million people affected. Most adults with depressive symptoms make at least one annual visit to a primary care physician (PCP). As such, primary care offers a ripe opportunity to identify and treat adults with depressive symptomatology. Yet, depression has historically been undertreated in primary ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Develop and Commercialize the Bayesian Dose-Response Modeling System and Services

    SBC: KS & ASSOCIATES LLC            Topic: NIEHS

    PROJECT SUMMARY Chemical risk assessment is widely applied in industries and regulatory agencies as an important tool to evaluate chemical toxicity in support of chemical registration, safety evaluation, and exposure limitation development. One of the most notable improvements in dose-response assessment - a required quantitative step in risk assessment - is the development of benchmark dose (BMD) ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. A user-friendly scalable microfluidic platform for enhanced neuron-cell culture

    SBC: Xona Microfluidics, Inc.            Topic: 101

    DESCRIPTIONprovided by applicantNeuron cell culture is widely used for studies in basic researchdrug discoveryand toxicity testingTraditional neuron cell culture approaches result in random growth of processes which prevent the study of their unique polarized morphologyOur goal is to provide robustuser friendlyand cost effective culture platforms to manipulate and access neurons and their subcellu ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease

    SBC: NEURODON, LLC            Topic: NIA

    Neurodon LLC proposes to conduct lead optimization and candidate-seeking activities on a novel series of neuroprotective small molecules that shows efficacy in a transgenic model of Alzheimer’s disease (AD). AD is a leading cause of death in the United States, with some estimates ranking it as high as third behind cardiovascular disease and cancer. Despite the enormity of this national public he ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Novel MRI Contrast Agent for Early Detection of Alcoholic Steatohepatitis

    SBC: INLIGHTA BIOSCIENCES L.L.C.            Topic: 999

    Abstract Chronic liver disease (CLD) is a major cause of morbidity and mortality worldwide[1-4]. Hepatic fibrosis can develop in patients with any type of chronic liver disease (CLD), including alcoholic liver disease (ALD), hepatitis C, hepatitis B, nonalcoholic fatty liver disease (NAFLD) and autoimmune hepatitis. The major clinical consequences of cirrhosis are liver failure and hepatocellular ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government